

30 day NICE TA recommendation from February 2023

Summary of decisions made regarding 30-day NICE TA861

Recommendations without significant financial/commissioning impact

NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/guidance relevance	Decision
<p>TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis</p> <p>Commissioning: ICS, tariff-excluded, 30 day TA</p> <p>Upadacitinib is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if:</p> <ul style="list-style-type: none"> tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and the company provides upadacitinib according to the commercial arrangement. 	01/02/23	Listed as RED drugs for other indications	Add to formulary as a RED drug in this indication, with a link to TA861.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.